Randomized controlled trials that have been used for the FDA approval of new anticancer drugs were sometimes based on a flawed design, with suboptimal control arms: “Using a suboptimal control arm may bias a trial in [more]
After the European Medicines Agency (EMA) approves a new cancer drug, reimbursement decisions by each country’s health authorities can take up to one year, with wide variations between countries. according to a study just presented [more]
Anna Wagstaff looks at changes in the business, regulatory and science arenas that could open the way to delivering better cancer treatments, faster and cheaper. Of 91 new therapies approved for solid tumours between 2002 [more]